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With the emergence of personalised cancer vaccines and more recently with the COVID-19 pandemic, the
increasing need for novel and disruptive manufacturing and supply chain strategies to deliver affordable
vaccines has been highlighted. Decision-support tools are essential to accelerate and enhance decision-making
during the development, commercialisation and distribution of prophylactic or therapeutic vaccines across the
globe. This presentation will share our most recent insights from UCL’s Bioprocess Decisional Tools research
on modelling the economics of integrated and intensified manufacturing technologies for viral vectors and
mRNA vaccines.
On the mRNA front, UCL collaborated with Univercells Technologies and Quantoom Biosciences to explore
novel identified, integrated and automated platforms for the production of personalised cancer vaccines, and we
evaluated the benefits and limitations of the technology across a range of demands and dose sizes.
Furthermore, we simulated the same manufacturing technology for the production of a prophylactic mRNA
vaccine against an infectious disease at a pandemic pace, focusing on the adequate and rapid supply of
vaccines in developing countries. The case study used the COVID-19 pandemic as a real-world example to
determine the necessary infrastructure and manufacturing capacity in Africa to support a rapid response across
the continent. In the analysis, we considered two vaccine technologies; an adenoviral vector and an mRNA
vaccine, aiming to determine the required facility footprint, the capital investment and the cost of goods.
Moreover, for each vaccine technology we compared an integrated with a conventional manufacturing platform
for a centralised and a regional manufacturing and supply chain network.
These case studies have highlighted the importance of utilising decision-support tools in bioprocessing to gain
an in-depth understanding of the necessary infrastructure and the associated cost to manufacture and supply
affordable vaccines.
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